NICOTINE POLACRILEX (nicotine) by Design Pharmaceuticals is pharmacologic action nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Approved for cholinergic nicotinic agonist [epc]. First approved in 2006.
Drug data last refreshed 20h ago
Pharmacologic Action Nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis…
Cholinergic Nicotinic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Nicotine Influence on the Retina Following the Use of Electronic Cigarette
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Worked on NICOTINE POLACRILEX at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.